OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award
The Republic of China Venture Capital Association hosted its “Venture Capital Star” event and award night on January 15, 2014, and OBI Pharma, Inc. was selected and given the “Best …
OBI Pharma Announces NT$ 1.5 Billion Capital Infusion
OBI Pharma, Inc. (GreTai Securities Market: 4174), announced a new round of financing amounting to NT$ 1.5 billion has been completed. This signals the beginning of a new era in …
OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards
18 July 2013 – ROC President Ma Ying-jeou attended 2013 BIO Taiwan Opening Ceremony and presented the “Company with the Greatest Potential Award” to OBI Pharma (GreTai Securities Market 4174). …
OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.
Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. (GreTai Securities Market Code 4174) held its first extraordinary shareholders’ meeting of the year on the morning of 7 February …
OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.
Taipei, Taiwan – 31 January 2013 – A recent paper published by the Academia Sinica explained that a new generation therapeutic cancer vaccine – Globo H-DT (OBI-833) – can effectively …
Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD
DIFICID® (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) TAIPEI, 20 July 2012 OBI Pharma, Inc. announced today that DIFICID® (Fidaxomicin) has …